NORTHERN TRUST CORP - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 40 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$30,000
-51.6%
92,115
+7.0%
0.00%
Q2 2020$62,000
+138.5%
86,055
+5.8%
0.00%
Q1 2020$26,000
-54.4%
81,3720.0%0.00%
Q4 2019$57,000
+58.3%
81,372
+50.2%
0.00%
Q3 2019$36,000
-60.0%
54,1780.0%0.00%
Q2 2019$90,000
-33.3%
54,1780.0%0.00%
Q1 2019$135,000
-2.2%
54,1780.0%0.00%
Q4 2018$138,000
-49.6%
54,1780.0%0.00%
Q3 2018$274,000
+52.2%
54,178
-2.0%
0.00%
Q2 2018$180,000
-4.8%
55,300
+5.8%
0.00%
Q1 2018$189,00052,2580.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 1,689,064$5,506,0003.35%
PERKINS CAPITAL MANAGEMENT INC 249,700$814,0000.58%
Private Wealth Partners, LLC 900,000$2,934,0000.49%
Diametric Capital, LP 60,752$198,0000.19%
Granahan Investment Management 915,449$2,984,0000.18%
B. Riley Wealth Advisors, Inc. 250,000$815,0000.11%
Kalos Management, Inc. 38,000$137,0000.06%
Spark Investment Management LLC 203,600$663,0000.04%
GSA CAPITAL PARTNERS LLP 199,500$650,0000.03%
Crow Point Partners, LLC 25,860$84,0000.02%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders